Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -63.04% is 34% above its 5-year average of -96.21%, near the high end of its 5-year range (-204.45%–-17.74%).
40.56% above its 12-month average of -106.06%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.15%.
RETURN ON ASSETS (ROA)
-63.04%
RETURN ON ASSETS (ROA) AVG TTM
-106.06%
RETURN ON ASSETS (ROA) AVG 3Y
-121.33%
RETURN ON ASSETS (ROA) AVG 5Y
-96.21%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.56%
CURRENT VS 3Y AVG
+48.04%
CURRENT VS 5Y AVG
+34.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-134.35%
vs the sector median at left
Bluejay Diagnostics, Inc.
Market Cap
$787624.00
Return on Assets (ROA)
-63.04%
TTM Avg
-106.06%
3Y Avg
-121.33%
5Y Avg
-96.21%
Market Cap
$707297.00
Return on Assets (ROA)
2.60%
TTM Avg
-212.84%
3Y Avg
-24543.27%
5Y Avg
-19977.79%
Market Cap
$878396.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$885939.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$888387.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$570131.00
Return on Assets (ROA)
-18.39%
TTM Avg
-65.88%
3Y Avg
-62.81%
5Y Avg
-52.14%
Market Cap
$1.02M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$1.11M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.14M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $787624.00 | -63.04% | -106.06% | -121.33% | -96.21% |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 2.60% | -212.84% | -24543.27% | -19977.79% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| HCW Biologics Inc. (HCWB)vs › | $570131.00 | -18.39% | -65.88% | -62.81% | -52.14% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -44.32% | -57.72% | -286.30% | -215.47% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -8.84% | -4.56% | 8.88% | 8.88% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -64.99% | -31.34% | -98.36% | -79.15% |
ROA
-63.0%
ROE
-77.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -96.20% |
| 2024-12-31 | -115.93% |
| 2023-12-31 | -204.45% |
| 2022-12-31 | -68.76% |
| 2021-12-31 | -17.74% |
| 2020-12-31 | -74.19% |
| 2019-12-31 | -82.67% |
